2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Neoplasm Metastasis
19
Neoplasms
17
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Liver Neoplasms
8
Glioblastoma
7
Sarcoma
6
Stomach Neoplasms
5
Sarcoma, Ewing
5
Ovarian Neoplasms
5
Osteosarcoma
5
Melanoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Leukemia, Myeloid, Acute
3
Colorectal Cancer Metastatic
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Advanced Colorectal Cancer
3
Thyroid Neoplasms
2
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
regorafenib
×
Clear all
NCT05594147
2023-11-07
ROCURS
Bayer
Completed
4,103 enrolled